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The first report of a disease now known as the acquired immune deficiency syndrome (AIDS) appeared in May 1981.' This highly lethal syndrome is characterised by unexplained opportunistic infections and aggressive Kaposi's sarcoma.' From the very beginning homosexual men were identified as the group at highest risk of AIDS, and its cause was tentatively linked with various exposures common to this group. These included infections with cytomegalovirus, Epstein-Barr virus, and hepatitis B virus and exposure to substances including amyl nitrite, to "antigen overload," and to semen.`In retrospect, such hypotheses failed to explain the epidemiology of the disease as AIDS was found to affect several different risk groups and was new to them all. 2 6 With the isolation of a human retrovirus as the aetiological agent of AIDS a clearer understanding of its natural history has emerged.
The cause of AIDS
The primary cause of AIDS, the human T cell lymphotropic virus type III (HTLV-III),78 also designated lymphadenopathy associated virus9 (LAV) or AIDS related virus (ARV),'0 belongs to a family of recently discovered human retroviruses. Retroviruses have been known for more than 50 years as causes of leukaemias, lymphomas, and immune deficiency conditions in animals. " Three types of human retroviruses have been characterised so far: HTLV-I, which is associated with adult human T cell leukaemia; HTLV-II, which was originally isolated from a patient with hairy cell leukaemia but has not been linked to any particular disease; and HTLV-III, which causes AIDS. Whereas HTLV-I and II are stable viruses (with a low replication rate and molecular stability), HTLV-III has a high replication rate'2 and shows variability in its env gene region between isolates."'"' All three retroviruses appear to cause prolonged infection of OKT4 T lymphocytes (and perhaps other tissues, including the central nervous system) by their ability to integrate proviral copies of their genetic material into the host genome. '5 Once infected a person may well stay infected for life.
Epidemiological studies have used the presence of antibody as the most practical measure of exposure to HTLV-III, and it is reliable with the following exceptions. Detection of HTLV-Ill specific antibodies may become less easy as the severity of the clinical illness increases; indeed, patients with advanced stages of AIDS may lose detectable HTLV-III antibodies completely. ' 7 Recently a decline in HTLV-III antibodies has been reported before the onset of the disease. , Loss of antibodies has also been reported in a clinically healthy spouse of a patient with AIDS but is not considered a frequent phenomenon.'9 Possibly some infected people have a persistent viraemia while being antibody negative. This occurs with hepatitis B, a virus with which HTLV-III shares some recognised patterns of transmission. A few people have been found to be positive for the HTLV-III virus but antibody negative20; some of these may have been caught in the "window" between infection and antibody production. We need to study longitudinal data on such cases to assess the extent of this phenomenon.
Latency between viral exposure and antibody development
The time that may elapse between infection with HTLV-III and antibody production has not been clearly defined; certainly it may be prolonged. Transfusion of plasma contaminated with HTLV-III to chimpanzees produced an active antibody response three to 12 weeks after exposure.2'1-2 In man probably the most reliable data have come from a case of nosocomial infection with blood from a patient with AIDS, in which seroconversion occurred between days 27 and 47 after the accidental injection. 24 In another single case a patient with haemophilia probably seroconverted as a result of exposure to contaminated factor VIII concentrate 44 days earlier.2" For parenteral exposures, therefore, four to seven weeks seems the most likely period for the development of antibodies. Not much is known about the latent period in cases of sexual transmission. One homosexual man who had anal intercourse after abstaining from sexual activity for six weeks seroconverted between 16 and 47 days.26
Detection of antibody
The antibody detection system used may be responsible for minor differences in the time at which a seroconversion is registered. The Western blot technique, considered by many to be the most specific confirmatory assay, is also sensitive: 6 it uses electrophoretic separation of virus proteins (p) and glycoproteins (gp) to give a profile of bands characteristic of HTLV-III when antibody positive sera are applied. The bands specifically recognised in relation to HTLV-III are p15-18, p24-25, gp4l-45, p53-55, and p64'627; these represent both viral core antigens and envelope antigens. Higher molecular weight glycoproteins (for example, gpl20 and gpl6O) may occasionally be seen in Western blots but may be detected more readily by a radioimmunoprecipitation assay. 8 On Western blot p24 and p55 bands generally appear earliest in seroconversion (R J Biggar et al, submitted for publication),'827 whereas p41 is seen more often in patients with AIDS. 27 The presence of gpl20 and gpl60, however, seems likely to be one of the most stable indicators of prior infection and antibody production. 28 The implications of patterns of antigen recognition are still under investigation, but some antigens are known to occur together naturally simply because of a precursor-product relation (for example, p24 and p55).
Seroepidemiological studies and blood bank screening programmes have mostly used the enzyme linked immunosorbent assay (ELISA)-because it is rapid and economical. It has proved to be sensitive and specific when dealing with sera from members of the different risk groups 
Modes of transmission
HTLV-III has been isolated from lymphocytes in peripheral blood, bone marrow cells, spinal fluid and brain tissue, lymph nodes, cell free plasma, saliva, semen, and tears.8 [45] [46] [47] [48] In theory exposure to any of these body fluids, if contaminated with the virus, represents a risk. In practice, however, the risk of infection seems to depend heavily on the route of exposure. More recently, changes in the T helper to suppressor ratio has been shown to be associated with duration of seropositivity in longitudinal follow up of homosexual men. 9 The inverted ratio is due initially to both a rise in T suppressor cells and a decline in T helper cells's 9 which makes the ratio the single best predictor of seropositivity.6 9 This figure is, however, not much different from what has been reported for HTLV-III seropositive people in general (see below).
The AIDS related complex is characterised by at least two symptoms and two or more laboratory findings consistent with AIDS and is highly correlated with HTLV-III seropositivity."" AIDS itself is a life threatening syndrome of conditions opportunistic in patients whose immunity has been weakened by HTLV-III infection. The many different manifestations have been described elsewhere.' 9 HTLV-Il and AIDS risk Clearly our estimates of the incidence of AIDS among people who are antibody positive for HTLV-III must be based on only few years' experience. The initial reports that described seropositive homosexual men in Denmark and New York City showed that 9-14% developed AIDS over a two year follow up.6" ' In a recent updated study, including five cohorts with a total of 281 seropositive people (homosexual men from New York, Washington, and Denmark, haemophiliacs from Pennsylvania, and parenteral drug users from New York), the three year incidence of AIDScalculated using the Kaplan-Meyer survival analysis-was 34% in Manhattan homosexual men and 15% in the four other cohorts combined (J J Goedert et Atlanta, Georgia, 1985) . This short incubation period may partly explain the fivefold higher estimated risk of AIDS in children compared with adults, although their immature immune system and the volume of blood given may also be relevant.
The African experience
Examination of specimens of stored serum has shown that HTLV-III was introduced into American homosexual men and hemophiliacs around 1977-8 and probably slightly later into European risk groups."9-4' 90 101 There is no conclusive evidence that the HTLV-III virus originated in Africa, but evidence suggesting an earlier origin there than elsewhere includes case reports consistent with AIDS among residents in Africa in the mid-1970s. ' The immunological and clinical implications of seropositivity in Africans are much the same as outside Africa.
Some clinical manifestations are more common in Africa, however, owing to a widespread distribution of some microorganisms in the African milieu"'3 for example, cryptococcal meningitis."'IN In addition, the aggressive form of Kaposi's sarcoma seen among European and American homosexual men with AIDS appears frequently in certain areas of Africa endemic for AIDS and is closely related to the presence of HTLV-III antibody.' By contrast, the endemic form of Kaposi's sarcoma, which has been recognised for decades in Africa, is unrelated to either HTLV-III infection"' or immunosuppression. 116 Preventive and future aspects
In terms of prevention much has already been accomplished by a better understanding of the natural history of HTLV-III infection. Changes in sexual behaviour aimed at reducing the spread of HTLV-III have been reported in homosexual communities,"7 screening programmes have been introduced for blood donors in the United States and Europe, and the heat treatment of factor concentrates has been developed and is commercially available. We may reasonably hope that haemophiliacs and patients receiving blood transfusions may disappear in the future from the list of people at exceptional risk, though AIDS or other HTLV-III related diseases will continue to appear in those already infected.
Efficient prevention is much more complicated in homosexual communities. A man who has reduced his number of partners from 10 to three within the past two years while seroprevalence rates in his community have increased from 10% to 33% remains at the same risk of infection. The growing rates of seropositivity in parenteral drug users are also of concern because preventive programmes have so often before failed in this group.
Nevertheless, even minor reductions of the rate with which HTLV-III is spread will have a large impact on the total number of infected persons a few years from now. Therefore, prevention programmes-including both education and counselling-should be given priority both nationally and locally. In general, promiscuity and anonymous sex should be discouraged. Not only blood donors but organ and sperm donors should be tested for antibodies before their donation is used at all. Women likely to be exposed to the virus should be tested before planning to become pregnant; those who are antibody positive should be advised not to become pregnant or to postpone the decision until we have more knowledge. Screening should be offered to pregnant women belonging to high risk groups-for example, parenteral drug users-especially in areas with high seropositive rates, for both counselling and eventual careful observation of the child. The results of case tracing among patients with syphilis suggest that such methods might also prove useful in tracing HTLV-Ill positive people in especially low incidence areas. Health care workers should be instructed to follow published precautions,"0 especially safe handling and disposal of needles and sharp instruments. Laboratories dealing with HTLV-III infected material should use disposable plastic products to replace needles and sharp instruments wherever possible.
More than half a million people in the industrialised world and probably even more in Africa may already have become infected with HTLV-III. Many of these will develop AIDS; possibly, too, other long term sequelae such as malignancy and chronic degenerative diseases may occur in coming decades among other HTLV-III infected people. Therefore, we cannot afford to wait for a vaccine or effective antiviral treatment to be developed but must immediately take the necessary precautions to prevent further spread of the virus.
